AbbVie inks $54M settlement to resolve Namenda 'pay-for-delay' lawsuit

A protracted legal fight over an alleged "pay-for-delay" deal on AbbVie's Alzheimer's disease drug Namenda may be nearing its end as the sides have reached a preliminary settlement.